Conatumumab
Based on 1 Customer Validation
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. .
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.90%
- CAS No.: 896731-82-1
- Masse moléculaire:145.44 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Human IgG1 kappa
Human
TNFRSF10B/TRAILR2/CD262
Conatumumab (0-10 μg/mL, 4 h) activates caspase-3/7 in Colo205, H-2122, and MiaPaCa2 cells[2].
Conatumumab (0-10 μg/mL, 24 h) reduces cell viability in sensitive tumor cell lines (Colo205, H-2122, and MiaPaCa2 cells)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Colo205, H-2122, and MiaPaCa2 cells
-
Concentration:0-10 μg/mL
-
Incubation Time:24 h
-
Result:Dose-dependently inhibited cell viability.
Conatumumab (2.5 μg, i.p., three times per week) enhances the antitumor activity of chemotherapeutics (CPT11, HY-16562) (80 mg/kg) in Colo 205 xenograft[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors[2]
-
Dosage:0, 0.1, 0.3, 1, 3, 10, 30, 100 μg
-
Administration:Intraperitoneal injection (i.p.), twice weekly.
-
Result:Dose-dependently inhibited tumor growth.
Induced caspase-3 activation in tumors (determined by IHC).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1.5X106 HEPG2 cells with Conatumumab (HY-P99260, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa, Isotype Control (HY-P99001, blue) was used as the isotype control. -
Immobilized HY-P7307 TRAIL R2/TNFRSF10B Protein, Human (HEK293) can bind Conatumumab. The EC50 for this effect is 2.37 ng/mL.
Chemical Information
-
CAS No. 896731-82-1
-
Appearance Liquid
-
Masse moléculaire 145.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Conatumumab]
-
Synonyms
AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91. [Content Brief]
[2]. Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)